apremilast  (Amgen)

Journal: iScience

Article Title: FDA-approved PDE4 inhibitors alleviate the dominant toxicity of ALS-FTD-associated CHCHD10 S59L in Drosophila and human cells

doi: 10.1016/j.isci.2026.114879

Figure Lengend Snippet: Effects of other PDE4 inhibitors on abnormal mitochondrial phenotypes (A) Representative images from CHCHD10 S59L expressing mitochondria cultured in DMSO, Apremilast (1 μM), and Rolipram (1 μM) containing media in HeLa cells. Cells were immunostained against anti- FLAG (red, CHCHD10 S59L ) and anti-TOM20 (white, mitochondria) antibodies. Arrows indicate accumulated parkin in the mitochondria. Scale bars, 20uM. (B) Graphical representation indicates the percentage of HeLa showing Parkin-YFP accumulation in CHCHD10 S59L expressing mitochondria. Data are shown as mean ± SD (one-way ANOVA and post hoc Dunnett’s test, two-sided, comparison with DMSO, ∗∗∗ p < 0.001, ∗∗∗ p < 0.01, and ∗ p < 0.05). (C and D) Mitochondrial Respiration by Seahorse XF Cell Mito Stress tests 24 hrs after CHCHD10 S59L transfection in DMSO, Apremilast, and Rolipram treated HeLa cells. Data are shown as mean ± SD (one-way ANOVA and post hoc Dunnett’s test, two-sided, comparison with DMSO, ∗∗∗ p < 0.001, ∗∗ p < 0.01, and ∗ p < 0.05).

Article Snippet: Apremilast , MedChem Express , Cat # HY-12085/CS-0671; CAS:608141-41-9.

Techniques: Expressing, Cell Culture, Comparison, Transfection

Journal: iScience

Article Title: FDA-approved PDE4 inhibitors alleviate the dominant toxicity of ALS-FTD-associated CHCHD10 S59L in Drosophila and human cells

doi: 10.1016/j.isci.2026.114879

Figure Lengend Snippet: Evaluation of mitophagy using the mito-QC reporter in CHCHD10 S59L -expressing cells Hela Parkin−YFP cells were co-transfected with CHCHD10, the mito-QC reporter system, and treated with the respective drug or DMSO. (A) Representative confocal images of CHCHD10 S59L -expressing HeLa cells transfected with the mito-QC reporter plasmid. Cells were treated with vehicle (DMSO), Forskolin (20 μM), Roflumilast (1 μM), or Apremilast (1 μM) for 24 h. Mitophagy events are visualized by mitolysosomes (mCherry + /GFP − puncta-arrows in inset). (B) Graphical quantification of cells with mitolysosomes (%). PDE4 inhibitor treatment significantly decreased mitophagy compared with DMSO controls ( p < 0.05, one-way ANOVA followed by post hoc Dunnett’s multiple comparison test; ∗ p < 0.05, ∗∗ p < 0.01 vs. DMSO). Data represented here mean ± SD from three independent experiments. Scale bars, 20 μm.

Article Snippet: Apremilast , MedChem Express , Cat # HY-12085/CS-0671; CAS:608141-41-9.

Techniques: Expressing, Transfection, Plasmid Preparation, Comparison

Journal: iScience

Article Title: FDA-approved PDE4 inhibitors alleviate the dominant toxicity of ALS-FTD-associated CHCHD10 S59L in Drosophila and human cells

doi: 10.1016/j.isci.2026.114879

Figure Lengend Snippet: Additive effects of Forskolin and PDE4 inhibitors on mitochondrial network integrity in CHCHD10 S59L -transfected HeLa cells HeLa cells were transfected with FLAG-tagged CHCHD10 S59L and treated with Forskolin (12.5 μM) and Apremilast (1 μM) or both for 24 h. (A) Representative images of cells immunostained with anti-FLAG (green, CHCHD10 S59L ), anti-TOM20 (Red, mitochondria), and DAPI (blue, nuclei). Scale bars, 20 μm. (B) Quantification of mitochondrial length. Combined treatment with Forskolin and Apremilast significantly restored mitochondrial network integrity compared with single-drug treatments ( p < 0.05, one-way ANOVA followed by post hoc Tukey’s test). Data are presented as mean ± SD (# p < 0.05 vs. DMSO; † p < 0.05 between indicated groups.).

Article Snippet: Apremilast , MedChem Express , Cat # HY-12085/CS-0671; CAS:608141-41-9.

Techniques: Transfection